Arcellx, Inc. (ACLX)
| Market Cap | 2.88B |
| Revenue (ttm) | 110.32M |
| Net Income (ttm) | -70.69M |
| Shares Out | 52.80M |
| EPS (ttm) | -1.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 589,937 |
| Open | 53.24 |
| Previous Close | 53.55 |
| Day's Range | 52.59 - 54.89 |
| 52-Week Range | 30.74 - 75.10 |
| Beta | 0.02 |
| Analysts | Strong Buy |
| Price Target | 74.18 (+36.11%) |
| Earnings Date | May 6, 2024 |
About ACLX
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treatin... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for ACLX stock is "Strong Buy." The 12-month stock price forecast is $74.18, which is an increase of 36.11% from the latest price.
News
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients w...
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
-- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractor...
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months – -- The estimated median p...
Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium
Shares of Arcellx Inc. ACLX, +4.33% were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.'s GILD, -0.28% Kite as part of an expand...
Kite and Arcellx Announce Expansion in Strategic Partnership
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced that the companies have expanded their existing c...
ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
-- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment -- -- Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma -- -- ...
Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights
-- Recently released ASH abstract for the company's Phase 1 CART-ddBCMA trial demonstrated that median duration of response, progression free survival, and overall survival not reached with median fol...
Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition
-- Abstract released today is from a June 2, 2023 data cut -- -- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA i...
Arcellx to Participate in Two Upcoming Investor Conferences
REDWOOD CITY, Calif. , Oct. 26, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients w...
Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results
-- Company expects to present preliminary data from iMMagine-1 study in 2H'24 -- REDWOOD CITY, Calif. , Aug. 14, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcellx, Inc. - ACLX
NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arcellx, Inc. ("Arcellx" or the "Company") (NASDAQ: ACLX). Such investors are advised to contac...
Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program
-- FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion -- REDWOOD CITY, Calif. , June 19, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX)...
Arcellx Provides First Quarter Financial Results
REDWOOD CITY, Calif. , May 8, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients wit...
Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
REDWOOD CITY, Calif. , April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients ...
Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
-- Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma -- -- Presented continued robust long-term responses from CART-ddBCMA...
Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference
REDWOOD CITY, Calif. , Feb. 21, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients w...
Arcellx to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif. , Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients wi...
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies' previously announ...
Gilead to co-develop Arcellx's multiple myeloma drug
Gilead Sciences Inc. GILD, +1.91% said Friday that it will co-develop and co-commercialize Arcellx Inc.'s ACLX, +7.22% multiple myeloma treatment candidate, which is currently in Phase 2 clinical tria...
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop ...
Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress
-- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 27 of 38 (71%) evaluable patients reached CR/sCR; 20 of 25 patients (80%...
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
-- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading reliable manufacturing -- -- Arcellx to receive $225M upfront payment; ...
Arcellx Reports Third Quarter 2022 Financial Results and Business Progress
-- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA -- -- Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 64th ASH Annual Meeting in...